A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis

Extracellular matrix interactions play essential roles in normal physiology and many pathological processes. While the importance of ECM interactions in metastasis is well documented, systematic approaches to identify their roles in distinct stages of tumorigenesis have not been described. Here we report a novel screening platform capable of measuring phenotypic responses to combinations of ECM molecules. Using a genetic mouse model of lung adenocarcinoma, we measure the ECM-dependent adhesion of tumor-derived cells. Hierarchical clustering of the adhesion profiles differentiates metastatic cell lines from primary tumor lines. Furthermore, we uncovered that metastatic cells selectively associate with fibronectin when in combination with galectin-3, galectin-8, or laminin. We show that these molecules correlate with human disease and that their interactions are mediated in part by α3β1 integrin. Thus, our platform allowed us to interrogate interactions between metastatic cells and their microenvironments, and identified ECM and integrin interactions that could serve as therapeutic targets.

[1]  B. Garmy-Susini,et al.  Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.

[2]  R. Dhir,et al.  Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. , 2010, Cancer research.

[3]  C. Fombrun,et al.  Matrix , 1979, Encyclopedic Dictionary of Archaeology.

[4]  Edi Brogi,et al.  Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs , 2011, Nature Medicine.

[5]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[6]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[7]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[8]  Y. Takenaka,et al.  Galectin-3 and metastasis , 2004, Glycoconjugate Journal.

[9]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[10]  Lu-Gang Yu The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression , 2007, Glycoconjugate Journal.

[11]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[12]  W. V. van IJcken,et al.  Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction , 2010, PloS one.

[13]  Derek Y. Chiang,et al.  Suppression of Lung Adenocarcinoma Progression by Nkx2-1 , 2011, Nature.

[14]  K. L. Woodward,et al.  A question of life or death. , 2001, Newsweek.

[15]  Shu Chien,et al.  Investigating the role of the extracellular environment in modulating hepatic stellate cell biology with arrayed combinatorial microenvironments. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[16]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[17]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[18]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[19]  S. Bhatia,et al.  An extracellular matrix microarray for probing cellular differentiation , 2005, Nature Methods.

[20]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[21]  W. Muller,et al.  Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. , 2004, Cancer cell.

[22]  E. Vokes,et al.  Phase II study of oxaliplatin (O) and paclitaxel (T) in advanced Non-Small Cell Lung Cancer (NSCLC) , 2000 .

[23]  Stephen Pulman,et al.  Building the Framework , 1996 .

[24]  R. Hynes,et al.  The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain , 2012, Proceedings of the National Academy of Sciences.

[25]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[26]  S. Weiss,et al.  Membrane Type I Matrix Metalloproteinase Usurps Tumor Growth Control Imposed by the Three-Dimensional Extracellular Matrix , 2003, Cell.

[27]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[28]  Mina J Bissell,et al.  Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[29]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[30]  Woodward Kl A question of life or death. , 2001 .

[31]  Howard Y. Chang,et al.  Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. , 2009, Cancer cell.

[32]  R. Bresalier,et al.  Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. , 1998, Gastroenterology.

[33]  I Salmon,et al.  Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor , 2002, Gut.

[34]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[35]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[36]  P. Sharp,et al.  A system for Cre-regulated RNA interference in vivo , 2008, Proceedings of the National Academy of Sciences.

[37]  F. O'Malley,et al.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Eisenstein,et al.  Role of galectin-8 as a modulator of cell adhesion and cell growth , 2004, Glycoconjugate Journal.

[39]  Steven A. Carr,et al.  The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices , 2011, Molecular & Cellular Proteomics.

[40]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[41]  Mary J. C. Hendrix,et al.  Reprogramming metastatic tumour cells with embryonic microenvironments , 2007, Nature Reviews Cancer.

[42]  R. Weinberg,et al.  Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.

[43]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[44]  C. Larabell,et al.  Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies , 1997, The Journal of cell biology.

[45]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[46]  Cheryl Regehr,et al.  BUILDING A FRAMEWORK , 2005 .

[47]  M. Bissell,et al.  Inability of Rous sarcoma virus to cause sarcomas in the avian embryo , 1984, Nature.

[48]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[49]  Daniel G. Anderson,et al.  Cell-compatible, multicomponent protein arrays with subcellular feature resolution. , 2008, Small.

[50]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[51]  Shu Chien,et al.  Combinatorial signaling microenvironments for studying stem cell fate. , 2008, Stem cells and development.

[52]  Gabriel A. Rabinovich,et al.  Galectins as modulators of tumour progression , 2005, Nature Reviews Cancer.

[53]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[54]  P. Steeg,et al.  Metastasis: a therapeutic target for cancer , 2008, Nature Clinical Practice Oncology.

[55]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.